证券代码：688767 证券简称：博拓生物 公告编号：2023-027 根据《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等相关 规定，现将公司董事会披露回购股份方案前一个交易日（2023 年 11 月 3 日）登 记在册的前十名股东和前十名无限售条件股东的名称、持股数量和持股比例情况 公告如下： | 序号 | 股东名称 | 持股数量（股） | 占无限售条件流通 股的比例（%） | | --- | --- | --- | --- | | 1 | 朱爱菊 | 1,600,000 | 3.97 | | 2 | 国泰君安证券资管－杭州银 行－国泰君安君享科创板博 | 1,218,264 | 3.03 | | | 拓生物 1 号战略配售集合资 产管理计划 | | | | 3 | 汪莉萍 | 801,600 | 1.99 | | 4 | 王伟红 | 800,000 | 1.99 | | 5 | 梁荣伟 | 732,089 | 1.82 | | 6 | 香港中央结算有限公司 | 620,093 | 1.54 | | 7 | 刘威 | 551,627 | 1.37 | | 8 | 蔡敏亚 | 550,025 ...

二、董事会会议审议情况 经全体参会董事表决，形成决议如下： （一）审议通过了《关于以集中竞价交易方式回购公司股份方案的议案》 证券代码：688767 证券简称：博拓生物 公告编号：2023-026 杭州博拓生物科技股份有限公司 第三届董事会第十二次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 杭州博拓生物科技股份有限公司（以下简称"公司"）第三届董事会第十二 次会议于 2023 年 11 月 3 日在公司会议室以现场与通讯相结合的方式召开，本会 议通知已于 2023 年 10 月 30 日送达公司全体董事。本次会议由董事长陈音龙先 生召集并主持，会议应参加表决董事 7 人，实际参加表决董事 7 人。本次会议的 召集、召开符合《中华人民共和国公司法》等法律、法规和《公司章程》的有关 规定。 董事会认为：公司本次回购股份将用于股权激励及/或员工持股计划，为维 护广大投资者的利益，增强投资者信心，同时促进公司稳定健康发展，有效地将 股东利益、公司利益和员工个人利益紧密结合在一起，公司本次回 ...

证券代码：688767 证券简称：博拓生物 公告编号：2023-025 杭州博拓生物科技股份有限公司 关于以集中竞价交易方式回购股份方案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 拟回购股份的用途：杭州博拓生物科技股份有限公司（以下简称"公司"） 回购股份拟在未来适宜时机用于股权激励及/或员工持股计划，并在股份回购实 施结果暨股份变动公告日后 3 年内转让；若公司未能以本次回购的股份在股份回 购实施结果暨股份变动公告日后 3 年内转让完毕，则将依法履行减少注册资本的 程序，未转让股份将被注销。 回购股份的价格：不超过人民币 40.00 元/股（含），该价格不高于公司董 事会通过回购决议前 30 个交易日公司股票交易均价的 150%。 回购股份的资金总额：回购的资金总额不低于人民币 5,000 万元（含）、 不超过人民币 10,000 万元（含）。 回购期限：自董事会审议通过本次回购股份方案之日起 12 个月内。 回购资金来源：公司自有资金。 相关股东是否存在减持计划： 截至本公告披露日，公司实际 ...

杭州博拓生物科技股份有限公司 第三届董事会第十二次会议 杭州博拓生物科技股份有限公司 独立董事关于第三届董事会第十二次会议相关事项的独立意见 根据《上市公司独立董事管理办法》、公司《独立董事工作制度》和《公司 章程》的有关规定，我们作为杭州博拓生物科技股份有限公司独立董事，对公司 第三届董事会第十二次会议的相关事项发表如下独立意见： 独立董事签署： 一、《关于以集中竞价交易方式回购公司股份方案的议案》的独立意见 我们认为： 1、公司本次回购股份符合《中华人民共和国公司法》《中华人民共和国证券 法》《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等法律法规、 规范性文件及《公司章程》的相关规定，董事会会议表决程序符合相关法律、法 规和《公司章程》的相关规定； 2、公司本次回购股份将用于股权激励及/或员工持股计划，为维护广大投资 者的利益，增强投资者信心，同时促进公司稳定健康发展，有效地将股东利益、 公司利益和员工个人利益紧密结合在一起，公司本次回购股份具有必要性； 3、公司本次股份回购资金总额不低于人民币 5,000 万元（含）、不超过人民 币 10,000 万元（含），本次回购股份的资金来源为公司 ...

Financial Performance - The company's revenue for Q3 2023 was CNY 100,162,558.53, a decrease of 56.96% compared to the same period last year[5] - Net profit attributable to shareholders was CNY 29,925,011.27, down 78.60% year-on-year[5] - The net profit after deducting non-recurring gains and losses was CNY 22,573,407.69, reflecting an 83.10% decrease compared to the previous year[5] - Total revenue for the first three quarters of 2023 was ¥312,238,836.62, a significant decrease from ¥1,756,664,370.19 in the same period of 2022, representing a decline of approximately 82.24%[20] - Net profit for the first three quarters of 2023 was ¥90,060,965.64, compared to a net loss of ¥885,426,852.43 in the same period of 2022, marking a turnaround in profitability[21] - The company achieved an operating profit of ¥91,093,805.66 in Q3 2023, a significant decrease from ¥1,040,889,850.16 in Q3 2022[21] - The total comprehensive income for the first three quarters of 2023 was ¥91,077,493.37, compared to ¥887,005,092.51 in the same period of 2022, reflecting a substantial decline[22] Assets and Liabilities - The total assets at the end of the reporting period were CNY 2,554,262,236.27, a decrease of 7.16% from the end of the previous year[5] - Total assets as of September 30, 2023, are approximately ¥2.55 billion, down from ¥2.75 billion at the end of 2022, a decrease of 7.15%[15] - Total liabilities decreased to ¥131,377,729.41 in Q3 2023 from ¥188,920,067.64 in Q3 2022, reflecting a reduction of approximately 30.49%[20] - Total equity attributable to shareholders decreased to ¥2,419,035,665.06 in Q3 2023 from ¥2,561,259,556.96 in Q3 2022, a decline of about 5.55%[20] Cash Flow - Cash flow from operating activities showed a significant decline, with a net amount of CNY 36,490,523.60, down 95.37% year-to-date[5] - In the first three quarters of 2023, the net cash flow from operating activities was ¥36,490,523.60, a significant decrease of 95.37% compared to ¥787,383,433.41 in the same period of 2022[25] - Total cash inflow from operating activities was ¥404,508,892.26, down 82.09% from ¥2,261,432,862.44 in the previous year[25] - Cash outflow from operating activities totaled ¥368,018,368.67, a reduction of 75.05% compared to ¥1,474,049,429.03 in 2022[25] - The net cash flow from investing activities was ¥107,005,914.12, a turnaround from a negative cash flow of ¥153,709,277.36 in the same period last year[26] - The net cash flow from financing activities was -¥236,743,434.40, consistent with the previous year's negative cash flow of -¥341,936,869.38[26] Shareholder Information - Total number of common shareholders at the end of the reporting period is 9,443[11] - The largest shareholder, Hangzhou Tuokang Investment Co., Ltd., holds 24,896,000 shares, accounting for 23.34% of total shares[11] - The company has a total of 10 major shareholders with varying ownership percentages, with the top three holding a combined 51.30%[12] Research and Development - Research and development expenses totaled CNY 15,156,563.71, down 36.76% year-on-year, while the R&D expense ratio to revenue increased to 15.13%[5] - Research and development expenses for the first three quarters of 2023 were ¥43,745,658.93, down from ¥93,275,444.52 in 2022, indicating a reduction of approximately 53.06%[20] Market and Product Development - The company attributed the significant declines in revenue and profit primarily to a sharp decrease in sales of COVID-19 testing products[9] - The company has not reported any significant new product developments or market expansions during this reporting period[13]

杭州博拓生物科技股份有限公司 关于收到公司实际控制人、董事长提议回购公司股 份的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 杭州博拓生物科技股份有限公司（以下简称"公司"）于2023年10月27日收 到公司实际控制人、董事长陈音龙先生《关于提议杭州博拓生物科技股份有限公 司回购公司股份的函》。提议内容主要如下： 一、提议人提议回购股份的原因和目的 基于对公司未来持续发展的信心和对公司价值的认可，为了维护广大投资者 利益，增强投资者对公司的投资信心，同时促进公司稳定健康发展，有效地将股 东利益、公司利益和员工个人利益紧密结合在一起，提议公司以自有资金通过集 中竞价交易方式进行股份回购，并在未来适宜时机用于股权激励或员工持股计划。 二、提议人的提议内容 1、回购股份的种类：公司发行的人民币普通股（A 股）。 证券代码：688767 证券简称：博拓生物 公告编号：2023-024 7、回购资金来源：公司自有资金。 三、提议人在提议前 6 个月内买卖本公司股份的情况 提议人陈音龙先生在提议前 6 个月内不存在买卖本 ...

Financial Performance - The company reported a half-year revenue of 688767 million, reflecting a significant growth compared to the previous period[1]. - The company's operating revenue for the first half of 2023 was ¥212,076,278.09, a decrease of 86.08% compared to ¥1,523,920,126.55 in the same period last year[22]. - The net profit attributable to shareholders for the first half of 2023 was ¥61,602,889.28, down 91.73% from ¥744,966,357.17 in the previous year[22]. - The net cash flow from operating activities was -¥19,018,026.32, a decline of 102.31% compared to ¥824,342,271.33 in the same period last year[22]. - Basic earnings per share for the first half of 2023 were ¥0.58, a decrease of 91.69% from ¥6.98 in the same period last year[23]. - The weighted average return on equity decreased to 2.41%, down 28.29 percentage points from 30.70% in the previous year[23]. - The total assets at the end of the reporting period were ¥2,527,969,286.38, a decrease of 8.11% from ¥2,751,217,156.02 at the end of the previous year[22]. - The net assets attributable to shareholders decreased to ¥2,389,225,695.51, down 6.72% from ¥2,561,259,556.96 at the end of the previous year[22]. - The company reported a total revenue of RMB 277.1 million for the first half of 2023, with a net profit of RMB 145.5 million, representing a significant increase compared to the previous year[69]. - Revenue from routine testing products (non-COVID) reached 184.73 million yuan, an increase of 24.73% year-on-year, and a growth of 128.14% compared to the same period in 2019[83]. Market Expansion and Product Development - The user base has expanded by 25%, reaching a total of 1.5 million active users[1]. - The company has provided a future outlook with a revenue growth guidance of 15% for the next quarter[1]. - New product development includes the launch of three innovative diagnostic kits, expected to increase market share by 10%[1]. - The company is planning market expansion into Southeast Asia, targeting a 20% increase in regional sales by the end of the fiscal year[1]. - A strategic acquisition of a local biotech firm is in progress, projected to enhance R&D capabilities by 30%[1]. - The company has launched several new high-quality diagnostic products, including new saliva drug testing kits and various testing reagents, enhancing its product line significantly[31]. - The company is actively pursuing new strategies for market expansion and product innovation to strengthen its competitive edge[31]. - The company is focusing on expanding its market presence through new product launches and international certifications[54]. - The company has successfully developed and launched multiple new diagnostic products, including a new type of saliva drug testing board and various rapid testing reagents, enhancing its product line and market position[75]. Research and Development - The company has established a research and development team of 140 members, with 21.05% of the total workforce dedicated to R&D, reflecting a strong commitment to innovation[72]. - The total R&D investment for the period was approximately ¥28.59 million, a significant decrease of 58.75% compared to ¥69.31 million in the same period last year[56]. - R&D investment accounted for 13.48% of operating revenue, an increase of 8.93 percentage points from 4.55% in the previous year[56]. - The company has made significant progress in IVDR certification, with the first batch of 69 products receiving CE certification, positioning it as a leading manufacturer in the drug abuse detection market[49]. - The company has developed a series of innovative products in the POCT industry, achieving multiple national product certifications and covering five major testing areas[47][48]. - The company is advancing multiple R&D projects, including a new product for rapid detection of chronic diseases with an investment of ¥20 million, which is currently in the development phase[60]. - The company has made advancements in microfluidic technology, launching the first generation prototype and focusing on high-sensitivity detection applications in non-laboratory environments[76]. - The company has developed a high-performance automated production system to enhance product quality and production efficiency[51]. Compliance and Governance - The board has confirmed that the half-year report is accurate and complete, with no major omissions[1]. - The company will comply with all relevant laws and regulations regarding the transfer of shares by its directors, supervisors, and senior management[139]. - The company commits to reasonable stock reduction based on financial planning and legal requirements, ensuring compliance with regulations[156]. - The company will ensure compliance with all relevant laws and regulations regarding share transfers and reductions[150]. - The company will implement measures to ensure that any violations of share lock-up commitments will result in the forfeiture of gains from share sales[183]. - The company will actively accept social supervision regarding the fulfillment of commitments made during the IPO process[181]. - The company will announce any violations recognized by regulatory authorities within two trading days and will initiate a repurchase plan within three months[165]. Risks and Challenges - The company faces risks related to high reliance on overseas sales, which could be adversely affected by international political and economic factors[95]. - There is a significant risk of a sharp decline in operating performance due to the decreased demand for COVID-19 testing products, which were a major revenue source in 2022[97]. - The company is exposed to inventory impairment risks as inventory levels remain high, potentially leading to losses if market conditions worsen[99]. - The company has a risk of core technology leakage, as most of its proprietary technologies are not patented and thus harder to protect legally[93]. - The decline in R&D expenses is primarily attributed to a decrease in demand for COVID-19 testing products, leading to reduced investment in related R&D[57]. Environmental and Social Responsibility - The company invested 340,300 CNY in environmental protection during the reporting period[128]. - The company has established an environmental management system and implemented various internal management regulations to enhance environmental risk management[130]. - The company promotes energy conservation and emission reduction by optimizing production processes and improving material utilization[131]. - The company adheres to national regulations regarding air conditioning temperature settings to control electricity consumption and carbon emissions[131].

证券代码：688767 证券简称：博拓生物 公告编号：2023-021 杭州博拓生物科技股份有限公司 首次公开发行战略配售限售股上市流通公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： （二）本次上市流通的限售股为公司首次公开发行战略配售限售股，战略配 售限售股股东 1 名，系国泰君安证裕投资有限公司，锁定期为自公司股票上市之 日起 24 个月，该部分限售股股东对应的股份数量为 1,157,742 股，占公司股本 1 总数的 1.0854%，具体详见公司 2021 年 9 月 3 日在上海证券交易所网站上披露 的《杭州博拓生物科技股份有限公司首次公开发行股票并在科创板上市发行结果 公告》。本次解除限售并申请上市流通股份数量 1,157,742 股，现锁定期即将届 满，将于 2023 年 9 月 8 日起上市流通。 二、本次上市流通的限售股形成后至今公司股本数量变化情况 本次上市流通的限售股属于首次公开发行战略配售限售股，自公司首次公开 发行股票限售股形成至本公告披露日，公司未发生因利润分配、公积金转增导 ...

杭州博拓生物科技股份有限公司 第三届董事会第九次会议 杭州博拓生物科技股份有限公司 第三届董事会第九次会议 综上,作为公司的独立董事,我们同意公司本次使用部分暂时闲置募集资金 进行现金管理事项。 杭州博拓生物科技股份有限公司 第三届董事会第九次会议 独立董事关于第三届董事会第九次会议相关事项的独立意见 根据中国证监会《上市公司独立董事规则》、公司《独立董事工作制度》和 《公司章程》的有关规定,我们作为杭州博拓生物科技股份有限公司独立董事, 对公司第三届董事会第九次会议的相关事项发表如下独立意见: 一、关于首次公开发行股票部分募投项目结项并将部分节余募集资金永久补 充流动资金的议案的独立意见 我们认为:公司首次公开发行股票部分募投项目"年产 4 亿人份医疗器(体 外诊断)产品扩建升级建设项目"与"体外诊断产品生产线智能化改造建设项目" 结项并将部分节余募集资金永久性补充流动资金事项符合《上海证券交易所科创 板股票上市规则《上市公司监管指引第2号 -- 上市公司募集资金管理和使用的 监管要求》《上海证券交易所科创板上市公司自律监管指引第1 号 -- 规范运作》 等有关法律法规、规范性文件以及公司《募集资金管理制度 ...

证券代码：688767 证券简称：博拓生物 公告编号：2023-019 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、募集资金基本情况 （一）实际募集资金金额和资金到账时间 根据中国证券监督管理委员会《关于同意杭州博拓生物科技股份有限公司首 次公开发行股票注册的批复》（证监许可〔2021〕2497号），同意杭州博拓生物 科技股份有限公司（以下简称"公司"）首次公开发行股票的注册申请。公司获 准向社会公开发行人民币普通股（A股）股票2,666.6667万股，发行价格为每股 人民币34.55元，募集资金总额为人民币92,133.33万元，扣除发行费用人民币（不 含增值税）9,196.41万元后，实际募集资金净额为人民币82,936.92万元。本次 发行募集资金已于2021年9月3日全部到位，并经中汇会计师事务所（特殊普通合 伙）审验，于2021年9月3日出具了《验资报告》（中汇会验〔2021〕6815号）。 （二）募集资金使用和结余情况 | 加：理财收入 | 1,317.83 | | --- | --- | | 减：手续 ...